WLF, I agree with that theory and I would add another tactic to their strategy. Lots of days I'll watch the trades and can see it happening, where there are several big buys at the higher asking prices, quickly followed by usually much smaller sales to the lower bid prices. Of course not all are part of an organized effort, but if the same folks interested in accumulating loads of the stock had acquired (and paid "others" to acquire) a significant number of shares while dirt cheap, they could also snatch up a hell of a lot of shares without even shorting. All they have to do, when limit orders with lower bids are sitting on the board, is keep unloading small numbers of shares at that lower bid price and they can keep the price down in a certain range as long as major news releases haven't run them over with renewed demand.This tactic won't work forever, as they have a finite number of shares that they can unload this way without someone losing money, and at some point that method simply won't be big enough to stop the huge buying interest that's coming. However, as long as they are successful in keeping the price in the sweet zone, many shareholders will become nervous and/or impatient and dump their shares "throwing in the towel" as they've had all the waiting they were prepared to take. These shares are what they refer to as "shaken out", and the orchestrators are more than happy to scoop them up. When they get near the tipping point, they stop and let the price come back up a bit to prevent a full blown crash which they don't want because they prefer to keep the share structure where it is or "poised" for explosive upward moves.
WLF, I agree with that theory and I would add another
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue ReadingTop 5 Most Recently Viewed Articles
Endava Investors: Legal Action Could Recover Your Losses
Endava got tangled in a class action lawsuit over securities fraud back in 2024. Investors were already feeling the squeeze as whispers about declining demand for its services echoed through the trading floor. You know how it goes—when rumors hit, shares take a dive faster than you can blink. Class Action Reality: Who Gets to Play? The lawsuit targeted shareholders who...
Continue Reading
New Mortgage Ratings Assigned to Deephaven Trust Portfolio
Introduction to Deephaven Residential Mortgage Trust 2024-1 In an important development within the non-prime mortgage market, KBRA has recently assigned preliminary ratings to eight classes of mortgage-backed notes from Deephaven Residential Mortgage Trust 2024-1 (DRMT 2024-1). This $514.6 million transaction comprises a unique pool of 1,330 residential mortgages,...
Continue Reading
Meta Platforms Declares Cash Dividend for Shareholders
Quarterly Cash Dividend Announcement from Meta Platforms The board of directors of Meta Platforms, Inc. (NASDAQ: META) has recently declared a quarterly cash dividend of $0.525 per share, benefitting shareholders holding both Class A and Class B common stock. This dividend reflects the company's ongoing commitment to returning value to its shareholders. Dividend Payment...
Continue Reading
Campine Expects Strong Financial Upsurge in 2024 Performance
Campine NV Forecasts Impressive Growth in 2024 Campine NV, a well-known name in the metals recycling and specialty chemicals sector, is gearing up for a promising financial year ahead. The company has recently indicated that it anticipates higher profits in 2024, thanks to favorable market conditions. Projected Revenue Growth for 2024 According to Campine's expectations,...
Continue Reading
Thumzup Media's Strategic Investment in Dogecoin Ahead of ETFs
Thumzup Media's Strategic Move into Dogecoin Thumzup Media Corporation (Nasdaq: TZUP) has made headlines with its latest purchase of Dogecoin, securing around 7.5 million tokens valued at approximately $2 million. This significant acquisition marks the company's first open-market investment in Dogecoin, reflecting a strong belief in the digital currency's potential for...
Continue Reading